An interventional study of Iron Supplement in Premature Birth, sponsored by Riccardo Pfister. Recruiting at 2 sites in Switzerland. Open to participants aged 14 Days to 14 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Riccardo Pfister · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Premature Birth with a site in Switzerland — 12 open to participants now, 14 under way, none of them phase 3. Premature Birth · Switzerland.
Among the 34 studies in Premature Birth with a site in Switzerland, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2024, is one of 15 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 28th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →12 of the 34 studies in Premature Birth with a site in Switzerland are open now. Recruiting first, the newest first:
Rea Diagnostics SA · Sites in Switzerland
Ages 18+ · Women only
University of Zurich · Sites in Switzerland
Ages up to 4 wk
Henner Hanssen · Sites in Switzerland
Ages 6–12 · Healthy volunteers
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages 35 wk–1 yrs · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 14 Days to 14 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 57 across the 20 interventional studies, 168 across the 14 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 34 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Riccardo Pfister as lead sponsor.
Riccardo Pfister has 1 study filed under Premature Birth — fewer than ten, so there is no comparison to draw.
2 of the studies in Premature Birth with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07237139University of ZurichPulmonary Volume Changes During Synchonized Noninvasive Positive Pressure Ventilation | 2026-12-31 |
| NCT07307365Rea Diagnostics SAEvaluation of the Clinical Performance of the PremaSure Kit to Assess Premature Delivery Risk in Symptomatic Pregnant Patients | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies in Premature Birth with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
BienFer is a double-blinded randomized controlled trial about iron substitution and abdominal pain. Premature babies and low birth weight babies have lower iron stores than term newborns and are therefore at greater risk of iron deficiency and anemia. Iron deficiency could have consequences for cerebral development. Ferric substitution reduces the risk of iron deficiency and anemia. It is common to replace premature babies with iron substitution between 2 weeks and 6 months of life. In practice, the medical staff notice that newborn with iron substitution have abdominal pain and constipation. A study in the adult population shows that alternate iron supplementation versus daily supplementation improved iron absorption, with no difference in hemoglobin level and decrease abdominal pain. Studies in children shows that intermittent iron supplementation do not change hemoglobin and ferritin level and improve adherence. There is no data comparing daily versus alternate supplementation in premature babies.
The aim of the study is to evaluate if alternate (4 times/week) iron supplementation is equivalent to daily iron substitution for hemoglobin values in premature babies between 28 0/7 weeks amenorrhea (WA) and 34 6/7 WA, and if it reduces abdominal discomfort and inflammation, and if it improves compliance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This arm will receive 2-3mg/kg/d of maltofer 4 times a day
Drug: Iron Supplement
This arm will receive 2-3mg/kg/d of maltofer 7 times per week.
Drug: Iron Supplement
The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week
Anemia at 6 months
Hemoglobin level
Time frame: 6 months
Anemia
Hemoglobin
Time frame: at 2weeks, 1 month, 2-3 months
Anemia
Hematocrit level
Time frame: at 2weeks, 1 month, 2-3 months
Ferritin
Ferritin
Time frame: at 2 weeks, 1 month, 2-3 months and 6 months
Ret-Hb level
Ret-Hb level
Time frame: at 2 weeks, 1 month, 2-3 months and 6 months
Transfusion
Number of patients needed a transfusion
Time frame: at 1 month, 2-3 months and 6 months
Therapeutic level
Number of patients needed to increase the iron substitution to a therapeutic level
Time frame: at 1 month, 2-3 months and 6 months
Evaluation of abdominal inflammation
Calprotectin level
Time frame: at 2 weeks and 2-3 months
Evaluation of abdominal inflammation
Hepcidin level
Time frame: at 2 weeks and 2-3 months
Evaluation of intestinal microbiota
Fecal sequencing
Time frame: at 2-3 months
Comorbidities
Number of retinopathy of prematurity (ROP)
Time frame: at 6 months
Comorbidities
Number of periventricular leukomalacia (PVL)
Time frame: at 6 months
Comorbidities
Number of sepsis
Time frame: at 6 months
Comorbidities
Number of intraventricular hemorrhage (IVH)
Time frame: at 6 months
Comorbidities
Number of bronchopulmonary dysplasia (BPD)
Time frame: at 6 months
Comorbidities
Number of necrotizing enterocolitis (NEC)
Time frame: at 6 months
Evaluation of weight gain
Tracking weight in Kilograms
Time frame: at 2 weeks, 1 month, 2-3 months and 6 months
Evaluation of height gain
Tracking height in Centimeters
Time frame: at 2 weeks, 1 month, 2-3 months and 6 months
Evaluation of the growth's parameter
Tracking head circumference in Centimeters
Time frame: at 2 weeks, 1 month, 2-3 months and 6 months
Evaluation of abdominal discomfort
Edin scale (0 (better outcome, no pain)-15 (worse outcome, pain))
Time frame: 3 times per week during hospitalization then 1 time per 2 weeks until 6 months
Evaluation of abdominal discomfort
Classify stools with Bristol scale (1 (severe constipation) -7 (severe diarrhea))
Time frame: 3 times per day during hospitalization then 1 time per 2 weeks until 6 months
Started Nov 2024 (actual). Primary completion is estimated for Sep 2026, 22 months after the start.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 22 months is close to that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron Supplement